These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17541882)

  • 1. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
    Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
    Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y; Gibel A; Yorkov V; Ritsner MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
    Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
    Montes JM; Rodriguez JL; Balbo E; Sopelana P; Martin E; Soto JA; Delgado JF; Diez T; Villardaga I
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):383-8. PubMed ID: 17129654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T;
    Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from ziprasidone im to oral formulation in agitated patients with acute exacerbation of schizophrenia: an open trial.
    Mautone A; Scarone S;
    Pharmacopsychiatry; 2011 Jul; 44(5):173-8. PubMed ID: 21751127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone-induced acute dystonia.
    Mason MN; Johnson CE; Piasecki M
    Am J Psychiatry; 2005 Mar; 162(3):625-6. PubMed ID: 15741487
    [No Abstract]   [Full Text] [Related]  

  • 15. Focus on ziprasidone.
    Green B
    Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL; Su TP; Chou YH
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ziprasidone-induced acute dystonia.
    Rosenfield PJ; Girgis RR; Gil R
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):546-7. PubMed ID: 17123682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
    Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
    Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
    Goff DC; McEvoy JP; Citrome L; Mech AW; Bustillo JR; Gil R; Buckley P; Manschreck TC; Achtyes ED; Macklin EA
    J Clin Psychopharmacol; 2013 Aug; 33(4):485-90. PubMed ID: 23775057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.